Androgel “Low-T” Litigation
Court: United States District Court for the Northern District of Illinois
In re Testosterone Replacement Therapy Products Liability Litigation, Case No.: MDL 2545
On January 1, 2014, the FDA issued an alert and announced that they were investigating the risk of stroke, heart attack, and death in men taking testosterone medications. The FDA was reacting to recent studies that suggested certain groups of men face a considerable risk of heart attacks if they take testosterone. On June 19, 2014, the FDA began requiring manufacturers of testosterone products to include a general warning in the drug labeling about the risk of blood clots in the veins, in response to postmarket reports of venous blood clots.
There are several manufacturers and testosterone medications at issue, including Abbvie and Abbot Laboratories, the makers of AndroGel—by far the most popular “Low T” product on the market. Other Defendants include Eli Lilly (Axiron), and Watson Laboratories (Androderm). Testosterone products are approved to treat men who lack testosterone or have low testosterone levels, in conjunction with an associated medical condition.
Wexler Wallace represents individuals who have suffered serious side effects from taking testosterone or “Low T” products. If you or someone you know has suffered health complications, contact us at 312.346.2222 for more information, or complete our online form.
We maintain the confidentiality of all inquiries and information provided.